Dimerix Limited (ASX:DXB)
0.1850
+0.0100 (5.71%)
May 29, 2026, 4:10 PM AEST
Dimerix Revenue
Dimerix had revenue of 2.12M AUD in the half year ending December 31, 2025, with 1,490.79% growth. This brings the company's revenue in the last twelve months to 7.42M, up 1,219.92% year-over-year. In the fiscal year ending June 30, 2025, Dimerix had annual revenue of 5.59M with 1,271.12% growth.
Revenue (ttm)
7.42M
Revenue Growth
+1,219.92%
P/S Ratio
14.98
Revenue / Employee
494.41K
Employees
15
Market Cap
111.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.59M | 5.18M | 1,271.12% |
| Jun 30, 2024 | 407.47K | 370.68K | 1,007.64% |
| Jun 30, 2023 | 36.79K | -6.43M | -99.43% |
| Jun 30, 2022 | 6.46M | 2.02M | 45.58% |
| Jun 30, 2021 | 4.44M | 2.10M | 89.65% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 16.28M |
| Immutep | 7.92M |
| Actinogen Medical | 7.36M |
| Alterity Therapeutics | 6.64M |
| Amplia Therapeutics | 5.01M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |
| Nyrada | 2.38M |
Dimerix News
- 3 months ago - Dimerix Quarterly report: H1 2026 - Filings
- 4 months ago - Dimerix Earnings release: Q2 2026 - Filings
- 7 months ago - Dimerix Earnings release: Q1 2026 - Filings
- 7 months ago - Dimerix Slides: Investor Presentation - Filings
- 9 months ago - Dimerix Slides: Investor Presentation - Filings
- 9 months ago - Dimerix Annual report: H2 2025 - Filings
- 10 months ago - Dimerix Transcript: Investor Update - Transcripts
- 10 months ago - Dimerix Slides: Investor Update - Filings